Harsha Rangachar, MD
Clinical research physician with extensive experience in clinical development, medical affairs, and clinical trials management from start up to close out.
EdiGene is a clinical-stage biotechnology company focused on leveraging the cutting-edge genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of genetic diseases and cancer. The company has established its proprietary ex vivo genome-editing platforms for hematopoietic stem cells and T cells, in vivo therapeutic platform based on RNA base editing, and high-throughput genome-editing screening to discover novel targeted therapies. EdiGene Biotechnology USA is located in Cambridge, Massachusetts, while EdiGene is headquartered in Beijing with a subsidiary in Guangzhou, China.
